Staples–Former Home Depot chief marketing officer Frank Bifulco has been hired as Executive Vice President/Marketing by the office supplies retailer, effective June 23. Separately, Goldman Sachs downgraded Staples to "sell" from "neutral", citing "structural challenges" that will make margin improvement difficult. At the same time, Goldman upgraded Staples rival Office Depot to "buy" from "neutral."
Arm Holdings–Apple is considering using Arm's chips in a new line of Macs, according to industry blog MacBidouille.
AstraZeneca—Pfizer said it would not make a formal offer to buy its rival drug maker. AstraZeneca had said that Pfizer's most recent informal bid still undervalued the company.
General Motors–GM is now under scrutiny in Canada, with officials looking into two fatal crashes in vehicles that were under recall for faulty ignition switches.
Bank of America–The bank was able to identify a $4 billion error in its capital calculations due to a change in wording on Federal Reserve forms, according to the Wall Street Journal. Bo A had disclosed that mistake in late April, ahead of a resubmitted capital plan due today.
Sony–The electronics company has set up two joint ventures to manufacture and sell its PlayStation console in China. Video game consoles had been banned in China from 2000 until this past January.
InterContinental Hotels Group–The world's largest hotel company reportedly rejected a $10.1 billion takeover bid from an unnamed U.S. bidder, according to Sky News.
Nordstrom–The upscale department store is seeking a potential buyer for its store-branded credit cards, according to Bloomberg.
IntercontinentalExchange Group–The New York Stock Exchange's parent is moving ahead with a plan for an IPO of European exchange EuroNext, according to Reuters. The listing could have a value of $2 billion or more.
Intuit–The maker of TurboTax and Quicken personal finance software is buying privately held bill-payment service Check Inc. for more than $300 million, according to Reuters.
Qiagen–Qiagen has received FDA approval for its gene-testing kit, which will identify which patients might best benefit from the Amgen Acolorectal cancer drug Vectibix.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at email@example.com